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ABSTRACT
Introduction: Thoracic aortic stent grafts are orders of
magnitude stiffer than the native aorta. These devices
have been associated with acute hypertension, elevated
pulse pressure, cardiac remodelling and reduced
coronary perfusion. However, a systematic assessment
of such cardiovascular effects of thoracic endovascular
aortic repair (TEVAR) is missing. The CardiOvascular
Remodelling following Endovascular aortic repair
(CORE) study aims to (1) quantify cardiovascular
remodelling following TEVAR and compare
echocardiography against MRI, the reference method;
(2) validate computational modelling of cardiovascular
haemodynamics following TEVAR using clinical
measurements, and virtually assess the impact of more
compliant stent grafts on cardiovascular
haemodynamics; and (3) investigate diagnostic
accuracy of ECG and serum biomarkers for cardiac
remodelling compared to MRI.
Methods and analysis: This is a prospective,
nonrandomised, observational cohort study. We will
use MRI, CT, echocardiography, intraluminal pressures,
ECG, computational modelling and serum biomarkers
to assess cardiovascular remodelling in two groups of
patients with degenerative thoracic aneurysms or
penetrating aortic ulcers: (1) patients managed with
TEVAR and (2) control patients managed with medical
therapy alone. Power analysis revealed a minimum total
sample size of 20 patients (α=0.05, power=0.97) to
observe significant left ventricular mass increase
following TEVAR after 1 year. Consequently, we will
include 12 patients in both groups. Advanced MRI
sequences will be used to assess myocardial and
aortic strain and distensibility, myocardial perfusion
and aortic flow. ECG, echocardiography and serum
biomarkers will be collected and compared against the
imaging data. Computational models will be
constructed from each patient imaging data, analysed
and validated. All measurements will be collected at
baseline (prior to TEVAR) and 1-year follow-up. The
expected study period is 3 years.
Ethics and dissemination: This study has been
approved by the University of Michigan IRB. The
results will be disseminated through scientific journals
and conference presentations.
Trial registration number: NCT02735720.
INTRODUCTION
Background
Thoracic endovascular aortic repair (TEVAR)
entails the implantation of a stiff stent graft
in a diseased or ruptured thoracic aorta. The
use of TEVAR is increasing rapidly and is
being employed in younger patients.1 2 For
instance, the rate of TEVAR for descending
thoracic aortic aneurysm (TAA) in Great
Britain has almost tripled between 2006 and
2010, from 0.45 to 1.27 cases per 100 000,
and more than doubled for type B aortic dis-
section from 0.22 to 0.50 cases per 100 000.2
Current stent grafts have biomechanical
properties that are several orders of magni-
tude stiffer than the native aorta.3 The elastic
Strengths and limitations of this study
▪ There are currently no systematic studies on the
effects of endovascular aortic repair on cardio-
vascular remodelling.
▪ The results will serve as a guide for clinicians,
stent-graft designers and researchers to continu-
ously press the need for improvement of stent
grafts.
▪ As a single-centre, nonrandomised, observational
cohort study, generalisability of results may be
limited; this will require replication at other
centres and patients populations.
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modulus of the thoracic aorta in a middle-aged partici-
pant is 0.44 MPa. Conversely, a typical stent graft has an
elastic modulus of 55.2 MPa.3 4 The impact of such a
stiff device on cardiovascular function has not yet been
elucidated, despite the critical role of aortic elasticity in
damping the highly pulsatile ﬂow entering the aorta
from the left ventricle (LV). The elastic aorta stores ﬂow
during systole and releases it in diastole. This phenom-
enon, known as the ‘Windkessel effect’, results in a
more continuous ﬂow pattern to the distal vascular
beds throughout the cardiac cycle. Alterations in aortic
stiffness have been linked to disease.5–7 The aorta stif-
fens naturally with age and also with smoking, high
cholesterol levels, genetic predisposition and stent
grafting.8–10 Pre-clinical and clinical studies have
reported acute aortic stiffening following TEVAR result-
ing in hypertension, elevated pulse pressure, reduced
coronary perfusion and adverse cardiovascular remod-
elling leading ultimately to heart failure.9–11 However,
these studies have important limitations such as animal
models not directly translatable to humans, retrospect-
ive design, use of echocardiography alone and mixed
(eg, abdominal and thoracic aneurysms) patient
populations.
We next provide an overview of several modalities used
to quantify cardiac remodelling. ECG is the most com-
monly used non-invasive test to assess cardiac structure
and function. However, this test has low sensitivity in
detecting LV hypertrophy.12 13 Nevertheless, it should be
noted that the combined use of ECG and serum cardiac
biomarkers has shown beneﬁcial results, which may offer
an easily available, minimally invasive diagnostic and
prognostic test for cardiac remodelling.14 15
Echocardiography
This is widely used to study cardiac remodelling.16 17
Takeda et al9 found an increase in LV mass and left atrial
volume following endovascular aortic repair through
echocardiography. Recently, our research group retro-
spectively investigated cardiac remodelling following
TEVAR using echocardiography. We enrolled all TAA
patients managed with TEVAR at our centre between
2012 and 2015. Patients with severe heart or heart valve
disease were excluded. Preoperative and postoperative
(1 year follow-up) echocardiography and CT data
were available for 6 patients. We observed an average LV
mass increase of 39% (n=6, p=0.047) at follow-up. This
motivates further research with larger sample size and
higher quality imaging since echocardiography is as-
sociated with low reproducibility and high operator-
dependency, even when using three-dimensional
echocardiography.17 18
Cardiac MRI
This is the gold standard to assess cardiac remodelling
due to its high resolution and tissue contrast, high
accuracy, lack of ionising radiation, and plethora of
functional, structural and anatomical parameters that
can be used to evaluate the heart condition.18 19 It has
been shown that MRI has signiﬁcantly higher reprodu-
cibility and lower operator-dependency than echocardi-
ography for diagnosing cardiac remodelling.18 Modern
sequences such as MRI Tagging, strain-encoding
(SENC) and Steady State Free Precession provide
detailed quantiﬁcation of cardiac and aortic strain and
distensibility, and ﬁrst-pass perfusion contrast-enhanced
MRI can assess coronary perfusion.20–23 Moreover,
phase contrast (PC) MRI offers a non-invasive tech-
nique to measure pulse wave velocity (PWV) along a
particular segment of interest.24 Using cardiac MRI as
research imaging modality may be challenging as it
requires local expertise, longer examination time and
higher costs than echocardiography. In 2011, our group
studied the relationship between aortic stiffness and
diastolic dysfunction in patients with heart failure with
normal ejection fraction (HFNEF) compared to con-
trols using MRI. Aortic stiffness was assessed using PWV
via PC MRI and the transit time method. Myocardial
regional function was evaluated by tissue strain via MRI
tagging, and LV diastolic function was assessed by the
early-to-late atrial ﬁlling ratio (E/A) (ﬁgure 1).20 The
results showed that aortic PWV was higher in HFNEF
than in volunteers due to reduced vessel compliance.
The E/A ratio and myocardial strain measurements
showed inverse correlations.
Computational Fluid Dynamics
Recent developments in computational ﬂuid dynamics
(CFD) are among the most promising means to
understand the effects of regional variations in mater-
ial properties and arterial geometry on local and sys-
temic haemodynamics.25 A preliminary CFD study
assessing the impact of systemic (ie, ageing) and loca-
lised stiffening (ie, ascending aortic stent-graft repair)
on cardiac function has been recently performed by
our group. The study demonstrated that increases in
LV contractility (20% for the ageing, 8.5% for the
stent-graft repair) and work (11% for the ageing, 5%
for the stent-graft repair) are required to maintain
baseline cardiac output (ﬁgure 2). These results
highlight that alterations in stiffness in a relatively
short segment of the aorta have comparable impacts
on those resulting from generalised age-induced
stiffening.
To date, the impact of stent grafts on cardiovascular
remodelling has not been assessed systematically. The
lack of qualitative data presses the need for prospective,
well-designed, controlled research to study such impact,
which is the purpose of this protocol.
Objectives and hypotheses
Our objectives are
1. To quantify cardiovascular remodelling following
TEVAR through MRI and intraluminal pressure mea-
surements. Echocardiography will be compared
against MRI to assess its diagnostic accuracy.
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2. To investigate the diagnostic accuracy of ECG and
serum biomarkers for evaluating cardiac remodelling
compared to MRI, the reference method.
3. To validate computational modelling of thoracic
aortic haemodynamics following TEVAR using the
acquired clinical measurements. Once validated,
computational analyses will be performed to virtually
assess the impact of more compliant stent grafts on
cardiac and aortic haemodynamics.
The ultimate goal of this study is to protect patients
from potential unknown adverse effects of TEVAR, thus
improving TEVAR-related outcomes. We hypothesise that
TEVAR stiffens the thoracic aorta resulting in adverse
cardiovascular remodelling, while more compliant stent
grafts reduce this impact.
METHODS AND ANALYSIS
Study design and settings
This is a single-centre, prospective, nonrandomised,
observational cohort study conducted at the Frankel
Cardiovascular Center at the University of Michigan
Health System, a large regional hospital with expertise
in managing aortic disease. All consecutive patients with
descending degenerative TAA or penetrating aortic
ulcers (PAU) will be evaluated by the cardiac surgeon in
Figure 2 Top: Arterial stiffness for a baseline ‘middle-age’
participant, an ‘old-age’ participant showing generalised
arterial stiffening and a ‘stent repair’ case with identical
stiffness to the baseline except for the ascending aortic
segment, in which a stent graft (presented in grey), whose
stiffness is 125× higher than the native aortic tissue, was
inserted. Bottom: Changes in LV function required to maintain
cardiac output following generalised (old age) or stent-induced
stiffening. Left: changes in cardiac contractility, as given by a
LV elastance function. Right: changes in LV work, estimated
by computed pressure–volume loops (unpublished data Lau
et al 2016). LV, left ventricle.
Figure 1 Top: MRI Tagging sequence to quantify myocardial
strain. SAX and 4CH tagged images at ED and ES. Bottom:
Transit time (Δt) between proximal and distal flow waveforms
measured with PC MRI sequences is used to evaluate PWV
in the aorta.20 4CH, four-chamber; ED, end diastole; ES, end
systole; SAX, short axis.
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charge and, if deemed eligible, invited to take part in
the study.
Participants
The patient population will consist of adult patients
(aged 18 years or older) with descending degenerative
TAA or with PAU managed with TEVAR (TEVAR group,
n=12) or with optimal medical treatment alone (control
group, n=12). Choice of management will be left to
the discretion of the care-taking physician, as well as the
size and manufacturer of the stent graft used. Patients
will be excluded if they present with any of the following
conditions: ejection fraction <35%; LV wall motion
abnormality; poor renal function (estimated glomerular
ﬁltration rate (eGFR) <60 mL/min/173 m2); pregnancy;
connective tissue disorder; signiﬁcant valve, lung or
congenital heart disease; history of cardiac or aortic
surgery; expected cardiac or aortic surgery within the
study period; and standard MRI contraindications (pace-
makers, non-compatible metal implants and
claustrophobia).
Procedures and standard care
The study ﬂow chart is illustrated in ﬁgure 3.
TEVAR group
Standard work-up examinations for TEVAR will be col-
lected, consisting of CT, echocardiography, brachial
blood pressure, heart rate, ECG and blood tests. Once
consent is conﬁrmed, and prior to the TEVAR proced-
ure (window of 0–30 days), a non-invasive MRI scan and
blood samples will be acquired in addition to the stand-
ard of care measurements. Intraluminal pressure mea-
surements will be collected during the TEVAR
procedure. One year (window of 275–455 days) follow-
ing TEVAR, the participant will undergo a second MRI
study in addition to the standard clinical imaging
follow-up CT scan. Measurements of brachial blood pres-
sure, heart rate, ECG and blood testing will also be
repeated at follow-up.
Control group
Patients with stable degenerative TAA or PAU not requir-
ing aortic repair are monitored in the outpatient clinic
as standard of care. We will collect standard-of-care mea-
surements on brachial blood pressures and heart rates
in these patients. In addition, these participants will
undergo an ECG, blood testing and one MRI scan at
baseline. One year (window of 275–455 days) after base-
line, this group will undergo a second MRI study, with
subsequent brachial blood pressure and heart rate mea-
surements, ECG and blood testing.
Blood testing
We will acquire the following cardiac biomarkers: B-type
natriuretic peptide (BNP), N-terminal of the prohor-
mone brain natriuretic peptide (NT-pro-BNP), and
Troponin T. In addition, standard blood tests will be col-
lected, which include complete blood count with plate-
lets (ie, white cell counts, haemoglobin, haematocrit
and red blood cells) and a basic metabolic panel
(including sodium, potassium, glucose and calcium).
Echocardiography
Preoperative echocardiography is standard of care in all
patients requiring TEVAR. The obtained echocardio-
graphic measurements (LV mass index, left atrial
volume index and E/A ﬁlling ratios) will be collected
and compared to the preoperative MRI data.
Intraluminal pressure
During TEVAR, an angiography will be performed as
standard of care. Intraluminal pressure measurements
will be conducted in the TEVAR group, using the cathe-
ters and guidewires that will be already in place for the
deployment of the stent graft, as is common practice at
the University of Michigan Health System.
Magnetic resonance imaging
Table 1 summarises the MRI sequences used in this
study, which are approved either by FDA or by IRB. The
protocol will be built and imaging parameters optimised
by E.I.
PC MRI measurements will be acquired at different
levels of the thoracic aorta using through-plane velocity
encoding. Images will also be captured in an oblique
sagittal view (in-plane velocity encoding) to estimate the
aortic vessel wall stiffness via PWV measurements. PC
MRI images will be acquired across the mitral valve to
evaluate the LV diastolic function through the measure-
ment of E/A ﬁlling ratios. Measurements from the cine
images will include LV volume, LV mass and left atrial
volume. MRI Tagging or SENC will be used to measure
different components of myocardial strain in standard
short-axis and four-chamber views.
Figure 3 Patient population and
clinical measurements of our
study. BP, blood pressure; HR,
heart rate.
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Table 1 Overview of performed MRI sequences
Sequence Description Analysis Variables measured
Estimate
time
Cine Steady State Free
Precession or
gradient-refocused echo
A stack of cine short-axis images covering
the whole heart, as well as 4-chamber and
2-chamber images, will be acquired.
A radiologist (PA) will analyse the
images using Medis QMass software.
The endo- and epicardial ventricular
boundaries will be determined to
measure ventricular volumes, function
and mass, as well as left atrial volume.
Ventricular volumes and myocardial
mass to evaluate ventricular dilation and
hypertrophy (all measurements will be
normalised by the patient’s body surface
area). Left atrial volume.
15 min
Trans-mitral VENC Trans-mitral PC velocity-encoded flow
images will be acquired. VENC parameter
setting will be adjusted to avoid velocity
aliasing.
PA will analyse the images using Medis
QFlow software. The mitral valve
boundary will be determined through all
phases, from which E/A ventricular
filling ratio, will be determined.
Ventricular early-to-atrial filling ratio, as a
measure of ventricular diastolic function.
2–3 min
VENC across the aorta VENC PC flow images will be acquired at 4
different locations (ascending aorta, aortic
arch branches, proximal descending aorta
and at the level of the diaphragm). VENC
setting will be adjusted to avoid velocity
aliasing.
PA will analyse the images using Medis
QFlow software. The cross section of
the aorta will be determined through all
phases, from which velocity and flow,
will be determined. Further, EI will
analyse the images using in-house
software developed with Matlab to
measure PWV.
Blood flow and velocity patterns at
different cross sections of the aorta, as
well as PWV as a measure of aortic
stiffness.
25 min
(total)
SENC/MRI Tagging (IRB
approved)
SENC or conventional tagged images will
be acquired at the basal, mid-ventricular
and apical short-axis slices, as well as in a
4-chamber slice.
An MRI physicist (EI) will analyse the
images using Diagnosoft software to
measure myocardial strain.
Regional myocardial strain. 10 min
Perfusion Myocardial perfusion images will be
acquired after administration of
gadolinium-based contrast agent under
pharmacological stress.
PA will analyse the images visually and
using Medis QFlow software to
determine any perfusion defects as
well as the myocardium contrast uptake
and washout curves.
Myocardial perfusion defects, and
contrast uptake and washout patterns.
10 min
PC, phase contrast; PWV, pulse wave velocity; SENC, strain encoding; VENC, velocity encoding.
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SENC sequences will measure cardiac and aortic
strains. Cine images will be used to measure strain of the
thoracic aorta through measurements in the ascending
aorta just distal to the coronary branches and proximal
to the coeliac trunk. The sequence is obtained in
accordance with FDA safety guidelines. The total antici-
pated scan time is ∼1 hour. We will use a 3T scanner to
gain from the double signal-to-noise ratio provided by
this higher ﬁeld strength compared to 1.5T scanners.
Interobserver and intraobserver variability analyses (with
P.A. and E.I. as observers) will be computed to validate
reproducibility.
Computational fluid dynamics
CFD has been used profusely in the past decade for the
investigation of haemodynamics in complex anatomical
models built from image data. The so-called ‘image-
based modelling’ paradigm uses anatomical data
(obtained from CT or MRI images) to create a 3D com-
puter model representing the blood vessels of interest
where the simulation of haemodynamics will be per-
formed. Additional physiological measurements of ﬂow,
pressure or wall motion are used to inform the ‘bound-
ary conditions’ of the simulation. Computational ana-
lyses, usually requiring high-performance computing
hardware, are performed, and detailed descriptions of
haemodynamic quantities such as velocity, pressure and
wall shear stress are obtained for the entire volume of
interest. CFD techniques have been recently approved
by the FDA for non-invasive assessment of coronary
stenosis.26
Using the imaging and clinical data, simulations of
blood ﬂow and pressure will be performed in the
High-Performance Computer cluster ‘Flux’ at the
University of Michigan. The parameters of the simula-
tions will be iteratively adjusted until clinical data on
ﬂow, pressure and wall motion are matched within ±5%.
Highly detailed descriptions of velocity, ﬂow, pressure,
wall shear stress and other haemodynamically signiﬁcant
quantities will be obtained. Once the models are vali-
dated against clinical data, additional computational
analyses will be performed to virtually assess the impact
of more compliant stent grafts on cardiac and aortic
haemodynamics.
Outcome measures
Primary outcome measures
The primary outcomes are LV mass, E/A ratios, aortic
ﬂow (in the ascending aorta, all arch branches, proximal
descending aorta and distal descending aorta), myocar-
dial and aortic strain, central aortic PWV and myocardial
perfusion.
Secondary outcome measures
The secondary outcome measures are as follows: diag-
nostic accuracy for cardiac remodelling of ECG alone, as
well as in combination with BNP, NT-pro-BNP and
Troponin T compared to MRI; validation of
computational modelling of thoracic aortic haemo-
dynamics following TEVAR against intraluminal pres-
sures and MRI; and performance of more compliant
stent-graft designs on aortic haemodynamics.
Statistical methods
Sample size calculation
A sample size calculation was performed for the primary
outcome: signiﬁcant LV mass increase within 1 year fol-
lowing TEVAR. Our preliminary echocardiographic data
of TAA patients treated with TEVAR at the University of
Michigan Health System (Nauta et al, unpublished data,
2016) revealed an average LV mass increase of 39%
(p=0.047) at 1-year follow-up. Power analysis for a
Mann–Whitney U test, based on these preliminary data,
revealed that for a signiﬁcant threshold of 5% (p <0.05,
two-sided test), a total sample size of 20 patients (α=0.05,
power=97%) would be needed to observe a signiﬁcant
effect of TEVAR on LV mass increase. To ensure a
margin of error, we aim to include 12 TEVAR patients
and 12 control patients.
Statistical analysis
Statistical analysis will include descriptive and compara-
tive studies of clinical measurements and data acquired
from computational modelling. We will assign patients to
either the TEVAR or control group. Subanalysis will
include grouping by stent-graft type and length, gender
and age. The patients identifying information and pro-
tected health data will be dealt with according to Health
Insurance Portability and Accountability Act (HIPAA)
guidelines. Categorical variables will be compared using
the χ2 test or Fisher’s exact test, and continuous vari-
ables will be analysed using Student’s t-test or the
Mann–Whitney U test, as appropriate. Log-rank tests will
be performed to compare between-group differences.
Changes in haemodynamics will be evaluated by
Wilcoxon’s signed rank testing. A p value of <0.05 will
be considered signiﬁcant.
Ethics and dissemination
Assessment of risks
This study adds little risk to the standard of care for
these patients. The main added risks include blood
testing, use of a gadolinium-based contrast agent and
intraluminal pressure measures. Gadolinium is asso-
ciated with a minor risk (∼2%) of headache, nausea,
hives, temporary low blood pressure and rarer side
effects including renal failure and allergic reactions.
Intraluminal pressure measurement carries nearly no
additional risks since the guidewires will already be in
place for the TEVAR procedure.
Informed consent
Consent will be obtained during standard clinical visits
required for surgery or follow-up for medical manage-
ment. The patient and his/her family members, if
present, will be given information about the study and
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any alternative treatments that are available. The
informed consent process will be documented and
attached to the signed informed consent document. A
copy will be given to the patient and uploaded in the
patients’ electronic dossier. The original, signed hard-
copy will be kept in the subject binder.
Confidentiality/security
The study team can access data linked to a participant’s
identity. The patient privacy will be protected by a
secured database that will be maintained and saved in a
separate location from the research records. Only those
directly involved with this study will have access to the
records. The research records, data and specimens will
be protected against inappropriate use or disclosure, or
malicious or accidental loss or destruction by keeping
them in a locked ofﬁce with restricted access. Blood
samples will be processed, analysed and then destroyed.
Furthermore, there will be restrictions on copying study-
related materials. All digital data will be kept on secure
laptops, with individual ID and password protection and
encryption of digital data.
No data will be generated that, if revealed, might
place the participants at risk of personal safety, criminal
or civil liability, or damage to their ﬁnancial standing,
employability or reputation, and no data will be pro-
vided to a repository as part of a data-sharing agree-
ment. At the end of the study, data will be retained for
record-keeping purposes for 7 years.
Patients are identiﬁed by direct identiﬁers stored on
data records (eg, name, initials, phone number or
medical record number) and indirect identiﬁers includ-
ing a link to direct identiﬁers. This is necessary because
the data must be linked to the patient for veriﬁcation
purposes. Link lists will be maintained and saved in a
separate location from the research records. Only those
directly involved with the study will have access to the
records. No individually identiﬁable sensitive informa-
tion will be disclosed.
DISCUSSION
The CardiOvascular Remodelling following Endovascular
aortic repair (CORE) study will systematically assess the
effects of TEVAR on cardiovascular function through a
unique data set consisting of serum biomarkers,
imaging, intraluminal pressure measurements and com-
putational modelling. This research is timely and clinic-
ally important since TEVAR is being performed
increasingly and long-term effects remain undeter-
mined. Detailed data on the cardiovascular effects of
stent grafting, such as provided by the CORE study, are
needed since its practice may extend towards the aortic
arch and ascending aorta in the near future, where the
stiffening impact could be more profound. Moreover,
the stiffening effects of current stent grafts may be of
particular importance in young patients as their hearts
and aortas are more compliant than those of older
patients. This calls for further evaluation since TEVAR is
performed increasingly in young patients. Future aortic
patients might beneﬁt from data provided by the CORE
study through improved aortic stent-graft designs and
long-term outcomes.
As a single-centre, nonrandomised, observational
cohort study, generalisability of results may be limited,
which will require replication at other centres and
patient populations. Moreover, potential loss of follow-up
may lead to a prolonged study period as such patients
will be excluded from the study. Control participants
managed with aortic repair during the follow-up period
may also lead to exclusion (in case of open surgery) or
to a switch to the TEVAR group, which might increase
the study period. Moreover, stent grafts of different man-
ufacturers will be used. Therefore, care should be taken
when translating our ﬁndings to devices other than
those used in this study. Finally, pressures in our CFD
models of control participants will rely exclusively on
non-invasive brachial pressure data, while models of
TEVAR patients will also rely on intraluminal pressure
data measured by a catheter.
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